Objective: To determine the association between use of vaginal estrogen and risk of a global index event (GIE), defined as time to first occurrence of coronary heart disease (CHD), invasive breast cancer, stroke, pulmonary embolism, hip fracture, colorectal cancer, endometrial cancer, or death from any cause.
T he genitourinary syndrome of menopause encompasses a constellation of symptoms, including genital symptoms of dryness, burning, and irritation; sexual symptoms of lack of lubrication, discomfort or pain, and impaired function; and urinary symptoms of urgency, dysuria, and recurrent urinary tract infections. 1 It is highly prevalent, occurring in 20% to 45% of menopausal women. [1] [2] [3] Genital atrophic changes may have detrimental effects on a woman's quality of life. 3, 4 Several clinical guidelines advocate local low-dose vaginal estrogen therapy, instead of systemic estrogen therapy, for the treatment of postmenopausal women with only vaginal symptoms (ie, without hot flashes). 1, 2, 5 Several formulations of low-dose vaginal estrogen therapy are available for treatment of the genitourinary syndrome of menopause, including topical creams, an intravaginal insert, and an intravaginal ring. In a recent Cochrane review, all appear to have similar efficacy and safety. 6 The use of some formulations of low-dose vaginal estrogens acutely increases serum estrogen levels, 7, 8 but maintenance levels remain in the normal postmenopausal range. 9 Randomized trials have shown that systemic estrogen is linked to increased risks of venous thromboembolism, stroke, and (with combination estrogen þ progestogen) invasive breast cancer. [10] [11] [12] Despite the selection and confounding bias that apply to observational studies, these adverse health risks of systemic estrogen have been demonstrated in observational studies. [13] [14] [15] [16] [17] Therefore, large prospective observational studies might demonstrate whether vaginal estrogen use confers similar risks. However, it is unknown whether low-dose vaginal estrogen confers similar risks. Potential systemic effects of vaginal estrogen are included as warnings on the package labeling for vaginal estrogen preparations. However, randomized controlled trials of vaginal estrogen therapy were not designed to examine major endpoints such as heart attack, stroke, pulmonary embolism (PE), deep vein thrombosis (DVT), cancer, or hip fracture. Several observational studies have examined breast cancer and fracture risk in relation to vaginal estrogen therapy. Specifically, a Finnish observational study found that the use of vaginal estradiol was not associated with increased risk of breast cancer (although oral and transdermal estradiol use were associated with increased risk), 18 and a Swedish case-control study suggested that current users of low-potency vaginal estrogen had lower hip fracture risk compared with never-users of estrogen. 19 In the recent American College of Obstetricians and Gynecologists Committee Opinion regarding route of estrogen administration and DVT, the conclusion was that vaginal estrogens (in contrast to oral systemic estrogens) are not associated with increased risk of venous thromboembolism, 20 but observational studies are lacking. 9 Observational studies of associations of vaginal estradiol use with risk of other types of cardiovascular disease (CVD) and overall mortality are similarly lacking, though one study without a placebo comparison group reported decreased risk of coronary heart disease and stroke death in vaginal estrogen users compared with the background population. 21 Long-term studies regarding endometrial safety of vaginal estrogen use are also needed 6, 9 ; one large Danish registry study that did not exclude users of systemic hormone therapy (HT) found a two-fold increased endometrial cancer risk among users of vaginal estrogen. 22 However, in our review of published studies, the overall balance of risks and benefits with the use of vaginal estrogens has not been studied in detail, even in observational studies.
The genitourinary syndrome of menopause does not improve without therapy and long duration of vaginal therapy is usually necessary. 3 The high prevalence of the genitourinary syndrome of menopause and its adverse impact on sexual function and quality of life for postmenopausal women underscore the clinical relevance of assessing the safety and efficacy of local low-dose vaginal estrogen use. The Women's Health Initiative Observational Study (WHI-OS) offers an opportunity to examine the longitudinal data regarding associations between vaginal estrogen use and cardiovascular, cancer, and other health outcomes among a large cohort of US women reporting information regarding vaginal estrogen therapy use and important covariates.
METHODS

Study population and design
The WHI-OS, conducted from 1993 to 2005, enrolled 93,676 postmenopausal women aged 50 to 79 years at one of 40 clinical centers nationwide to examine risk factors and biomarkers for disease in a large prospective cohort. Details of the inclusion and exclusion criteria and the recruitment process were previously described. 23, 24 Inclusion criteria were ages between 50 and 79 years and intention to maintain residence in the same geographic area for at least 3 years. Exclusion criteria included medical conditions conferring a predicted survival of fewer than 3 years, or conditions (eg, alcohol or drug dependency, dementia, or medical illness) that would be expected to interfere with retention. Institutional review board approval was obtained at each clinical center. Each participant provided written informed consent. After the main WHI-OS ended, the WHI Extension Study (WHI Extension I, Ext 1) collected additional follow-up data from 2005 to 2010, reflecting 7.2 years of median follow-up.
For the current analyses, of the 93,676 WHI-OS participants, we excluded data from women with prior breast, endometrial, or ovarian cancer (n ¼ 7,079), women for whom information was missing regarding hysterectomy status (n ¼ 454), women currently using oral or transdermal estrogen or progestogen any time during follow-up (n ¼ 41,630, censoring beginning at baseline for prevalent users or at time of subsequent initiation), women for whom data regarding menopausal HT use was missing (n ¼ 85), and women who did not provide follow-up data (n ¼ 473), resulting in an analytic sample of 45,663 women (Fig. 1) . Study participants could have initiated vaginal estrogen, or experienced hysterectomy, during the study follow-up, resulting in a sample size of 32,433 women without hysterectomy (of whom 3,003 women were users of vaginal estrogen during follow-up) and 14,133 women with hysterectomy (of whom 1,207 women were users of vaginal estrogen during follow-up).
Outcomes
Study outcomes were assessed using annual self-assessment questionnaires. The following events were adjudicated based on medical record review by WHI physicians: myocardial infarction, stroke, death from any cause, hip fracture, and any cancer. Incident venous thromboembolic events (DVT, hospitalization for PE) were ascertained based on self-report using annual questionnaires. Cause of death was determined CRANDALL ET AL at the Clinical Coordinating Center after medical record or death certificate review. The National Death Index, conducted serially, provided additional information on cause of death.
As for the WHI HT trials, the global index event (GIE) was defined as the time to first occurrence of CHD (nonfatal myocardial infarction or CHD death), invasive breast cancer, stroke, PE, hip fracture, colorectal cancer, endometrial cancer, or death from any cause through the end of WHI Ext I. 25 
Assessment of vaginal estrogen use
Use of vaginal estrogen was ascertained using selfassessment questionnaires at baseline, annually from years 3 through 8, and at Ext 1 year 4 ( Table 1) . Information regarding specific type of vaginal estrogen (cream, ring, or tablet) or dose was not collected (use of the vaginal estradiol ring was only assessed at the end of the follow-up period in the Extension Study, so users are not included in this analysis).
We imputed missing information regarding vaginal estrogen use from the previous year's questionnaire if the same preparation was reported in the year before, compared with the year after, the missing questionnaire.
Other measures
We used baseline questionnaires to collect information regarding age, race/ethnicity, education level, household income, medical history (previous cancer, cardiovascular disease, DVT, ParƟcipant inclusion by reported progestogen (P) use 1 PE, fracture, hypertension, or diabetes mellitus), reproductive history (oophorectomy, hysterectomy, age at menopause, age at first birth), medication use (past HT use, oral contraceptive use, aspirin use, or statin use), breast cancer risk factors, cigarette smoking, and alcohol intake (servings/week). Gail breast cancer risk score was calculated for each participant. 26 Physical activity (total metabolic equivalent-h/wk) was assessed using the WHI validated physical activity questionnaire. 27, 28 At baseline, using a standardized protocol, blood pressure, height, and weight were directly measured. Body mass index (BMI) was calculated as body weight in kilograms (kg) divided by the square of height in meters.
Role of the funding source
The WHI-OS was funded by National Institutes of Health. Representatives from the National Institutes of Health participated in the design, monitoring, and conduct of the WHI-OS.
Statistical analysis
We used Cox proportional-hazards models to examine associations between vaginal estrogen use and individual endpoints and GIE risk. The main predictor was time-varying exposure to vaginal estrogen. The time to outcome was computed from the date of enrollment to the date of the first event (among the events included in the GIE index), or last available follow-up visit, or end of study follow-up period, whichever came first. The end of the study follow-up period was defined as 2.5 years after the last ascertainment of vaginal estrogen use. Because of the different risk profiles of estrogen alone (in women with hysterectomy) and estrogen plus progestogen (in women without hysterectomy), we made the a priori decision to present the results separately for women with an intact uterus and women who have had a hysterectomy. Hysterectomy status was time-varying. Covariates were chosen a priori based on previously published studies and included age, education, past estrogen use, history of cancer other than breast, endometrial or ovarian cancer before study baseline, history of cardiovascular disease before study baseline, history of DVT or PE before study baseline, race/ ethnicity, baseline BMI, baseline diagnosis of diabetes, baseline physical activity (total metabolic equivalent-h/wk), hypertension, Gail breast cancer risk score, fracture after age 55 before study enrollment, smoking, income, and alcohol use (servings/wk) All analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC).
RESULTS
Mean follow-up duration was 6.4 years; median follow-up was 7.2 years. Among women who initiated vaginal estrogen during the follow-up period, median duration of use was 2 years. Among women already using vaginal estrogen at baseline, median duration of use was 3 years before enrollment in WHI. Among vaginal estrogen users, on average, use encompassed 40% of the time during follow-up. At baseline, mean (standard deviation) age of participants was 64.8 (7.4) years in women who did not use vaginal estrogen at any time during follow-up and 65.5 (7.0) years in women who used vaginal estrogen during follow-up. In the overall analytic sample (women with hysterectomy and women without hysterectomy combined), compared with nonusers of vaginal estrogen, vaginal estrogen users were less likely to be black or African American (4.9% vs 11.2%), Hispanic (4.4% vs 2.3%), current smokers (3.6% vs 7.4%), diabetic (3.0% vs 5.5%), and to have BMI 30 kg/m 2 (19.1% vs 29.9%); vaginal estrogen users were more likely to be white (89.2% vs 79.8%), college graduates (46.3% vs 37.8%), have household income $100,000, and to have BMI <25 kg/m 2 (45.5% vs 35.9%) ( Table 2 ). The same pattern was true when participants were stratified by hysterectomy status. At baseline, the frequencies of other cardiovascular risk factors, cardiovascular disease events before study enrollment, and previous cancer diagnosis were similar among users and nonusers of vaginal estrogen. Bilateral oophorectomy, BMI 30 kg/m 2 , treated hypertension, history of cardiovascular disease, and past use of HT were more frequent in women who had undergone hysterectomy than among women without hysterectomy. The frequencies of specific types of cardiovascular events and cardiovascular risk factors at baseline were similar in women with versus without hysterectomy. In the study cohort overall, after adjustment for age, education, past HT use, history of cancer, history of CVD, history of venous thromboembolism, race/ethnicity, BMI, diabetes, physical activity level, hypertension, Gail breast cancer risk score, previous fracture, smoking, household income, and alcohol intake level, the risk of invasive breast cancer, death, stroke, colorectal cancer, and venous thromboembolism were similar among users versus nonusers of vaginal estrogen (Table 3) . 
DISCUSSION
In this large prospective cohort study, postmenopausal women who used vaginal estrogen had similar risks of invasive breast cancer, stroke, colorectal cancer, endometrial History of cardiovascular disease includes a past history of myocardial infarction, stroke, or revascularization prior to study enrollment. d Not including breast, endometrial, or ovarian cancers (which were exclusion criteria). CHD, coronary heart disease; DVT, deep vein thrombosis; GIE, global index event (defined as time to first coronary heart disease, breast cancer, stroke, pulmonary embolism, hip fractures, colorectal cancer, endometrial cancer, or death); MET, metabolic equivalent task; NA, not applicable; PE, pulmonary embolism. 
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cancer, and PE/DVT than nonusers of vaginal estrogen. We did not find evidence for elevated risk of CHD or death in vaginal estrogen users compared with nonusers. Previously published studies of vaginal estrogen preparations have not focused on summary indices of risks versus benefits of vaginal estrogen preparations, nor have they focused on colorectal cancer, PE, or hip fracture as specific individual outcomes. However, our results are consistent with a few prospective observational studies that evaluated CHD, stroke, breast cancer, and endometrial cancer risk among vaginal estrogen users.
First, a nationwide cohort study in Finland from 1994 to 2009 found a lower risk for CHD death and for stroke death in vaginal estrogen users, compared with the background population 21 (of note, the background population of the Finnish study included women using both vaginal estrogen and systemic HT, and the study lacked a placebo group).
A second Finnish observational study with 648,022 women-years of follow-up found that the use of vaginal estradiol was not associated with increased risk of breast cancer. 18 Finally, with regard to endometrial cancer, two randomized controlled trials documented no increase in endometrial hyperplasia or cancer after 12 months of treatment with 10 mg estradiol vaginal tablets. 29, 30 However, in a study of all Danish women aged 50 to 79 years followed from 1995 to 2009 (representing 9 million person-years of follow-up), the relative risk of endometrial cancer was increased with vaginal estrogen (1.96 [1.77-2.17]). 22 The differences in results between the Danish study and the current study might be related to differing doses or formulations of vaginal estrogen preparations in the two studies, or due to the fact that we censored data from vaginal estrogen users if they initiated oral or transdermal progestogen.
Our findings help to fill important knowledge gaps regarding the safety of vaginal estradiol. Randomized trials have shown that systemic estrogen is linked to increased risks of venous thromboembolism, stroke, and (with combination estrogen þ progestogen) invasive breast cancer. [10] [11] [12] 31, 32 These risks of systemic estrogen and estrogen þ progestogen were adopted into estrogen class labeling that is applied to all estrogen preparations, despite the lack of clinical trial evidence demonstrating that vaginal estrogens confer these same risks. (Clinical trials of vaginal estrogens were not designed to evaluate most key clinical outcomes such as CVD and fracture.) Low-dose vaginal estrogen preparations approved by the US Food and Drug Administration carry the same boxed warning about health risks as systemic formulations of estrogen alone and combination estrogen þ progestogen. The boxed warning, which reflects estrogen class labeling, states: ''WARNING: endometrial cancer, cardiovascular disorders, breast cancer, and probable dementia.'' This warning is based on extrapolations of data from clinical trials of systemic HT, which involved substantially higher levels of systemic exposure. The boxed warning is not based on evidence from clinical trials of vaginal estrogen and may discourage the use of a highly effective local treatment for a common condition with adverse effects on quality of life. 33 Currently, the US FDA is considering a proposal to modify package labeling so that it better reflects the safety profile of vaginal estrogen.
In the short term, serum levels of estrogens may rise with use of vaginal estrogen. A study using modern mass spectrometry assays of estrogen levels showed that the use of conjugated equine estrogens vaginal cream (Premarin 0.625 mg) caused a five-fold increase in serum estradiol after 1 week of daily treatment in postmenopausal women. 7 However, estrogen levels do not increase above the postmenopausal range with initial daily dosing during use of the estradiol vaginal insert (Vagifem 10 mcg), 34 and during the maintenance phase of low-dose vaginal estrogen therapy, blood levels remain in the normal postmenopausal range. 9 Our study has limitations. Although we adjusted for multiple potential confounders, there could have been residual confounding in this observational study. There have been reports of alterations in serum lipoproteins and increased bone density associated with low-dose vaginal estradiol rings. 35, 36 Whereas the lower CHD risk that we observed in vaginal users was consistent with other observational studies of oral HT, clinical trials have not addressed the effects of vaginal estrogen on clinical cardiovascular events. In addition, we could not compare health outcomes among the individual types of vaginal estrogen preparations (eg, estradiol ring, vaginal estradiol tablet, estrogen cream). Study strengths include the prospective data collection, the large sample size, the availability of detailed information regarding relevant confounders, and the adjudication of all GIE events except PE/ DVT. To our knowledge, this is the first large prospective study to evaluate the overall health risks and benefits of vaginal estrogen therapy.
CONCLUSIONS
In conclusion, we did not observe an increased risk of cardiovascular disease or cancer among women using vaginal estrogen compared with nonusers. These findings should provide reassurance to women and their health providers regarding the safety of vaginal estrogen and will help to inform menopausal HT clinical decision-making.
